Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Giovanni Triolo, Andre Beaulieu, Josef Rovensky, Rieke Alten, Cesar Ramos-Remus, Thasia Woodworth, Josef S Smolen, Andrea Rubbert-Roth, Emma Alecock

    Risultato della ricerca: Article

    993 Citazioni (Scopus)
    Lingua originaleEnglish
    pagine (da-a)987-997
    RivistaThe Lancet
    Volume371
    Stato di pubblicazionePublished - 2008

    All Science Journal Classification (ASJC) codes

    • Medicine(all)

    Cita questo

    Triolo, G., Beaulieu, A., Rovensky, J., Alten, R., Ramos-Remus, C., Woodworth, T., Smolen, J. S., Rubbert-Roth, A., & Alecock, E. (2008). Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. The Lancet, 371, 987-997.